Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

Son, Jang Won; Kim, Sung‐Rae

doi:10.4093/dmj.2020.0258

Cited by 88 publications

(92 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study including 32 patients with CKD stages 3-5 showed significant weight loss and no serious adverse events in this population (75). Furthermore, Son JW et al recommended that both orlistat and liraglutide can be carefully used in CKD patients with obesity (114).…”

Section: Pharmacological Management Of Obesitymentioning

confidence: 87%

“…As Son JW et al mentioned, the weight loss effect of these antiobesity drugs can be ranked as follows: phentermine/topiramate CR > liraglutide 3.0 mg > naltrexone ER/bupropion ER > orlistat. New clinical trials are ongoing to study new anti-obesity drugs, such as sodium-glucose cotransporter two inhibitors, other GLP-1 receptor agonists, dopamine reuptake inhibitors or mineralocorticoid receptor agonists (114). Obesity therapies goal is to treat adipose tissue dysfunction, excessive body fat and diseases that are secondary to increased body fat and its adverse consequences, as renal impairment.…”

Section: Pharmacological Management Of Obesitymentioning

confidence: 99%

See 1 more Smart Citation

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management

et al. 2021

View full text Add to dashboard Cite

Obesity is one of the epidemics of our era. Its prevalence is higher than 30% in the U.S. and it is estimated to increase by 50% in 2030. Obesity is associated with a higher risk of all-cause mortality and it is known to be a cause of chronic kidney disease (CKD). Typically, obesity-related glomerulopathy (ORG) is ascribed to renal hemodynamic changes that lead to hyperfiltration, albuminuria and, finally, impairment in glomerular filtration rate due to glomerulosclerosis. Though not only hemodynamics are responsible for ORG: adipokines could cause local effects on mesangial and tubular cells and podocytes promoting maladaptive responses to hyperfiltration. Furthermore, hypertension and type 2 diabetes mellitus, two conditions generally associated with obesity, are both amplifiers of obesity injury in the renal parenchyma, as well as complications of overweight. As in the native kidney, obesity is also related to worse outcomes in kidney transplantation. Despite its impact in CKD and cardiovascular morbility and mortality, therapeutic strategies to fight against obesity-related CKD were limited for decades to renin-angiotensin blockade and bariatric surgery for patients who accomplished very restrictive criteria. Last years, different drugs have been approved or are under study for the treatment of obesity. Glucagon-like peptide-1 receptor agonists are promising in obesity-related CKD since they have shown benefits in terms of losing weight in obese patients, as well as preventing the onset of macroalbuminuria and slowing the decline of eGFR in type 2 diabetes. These new families of glucose-lowering drugs are a new frontier to be crossed by nephrologists to stop obesity-related CKD progression.

show abstract

Section: Pharmacological Management Of Obesitymentioning

confidence: 87%

Section: Pharmacological Management Of Obesitymentioning

confidence: 99%

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Weight control drugs or functional foods are known to control obesity through various mechanisms. Obesity can be suppressed by mechanisms such as the inhibition of sugar absorption, the inhibition of fat absorption, appetite suppression, and adipocyte differentiation inhibition [ 51 , 52 ]. Therefore, the search for various anti-obesity substances and the analysis of anti-obesity mechanisms will enable people to more actively select anti-obesity strategies.…”

Section: Discussionmentioning

confidence: 99%

Anti-Obesity Effect of Hot Water Extract of Barley Sprout through the Inhibition of Adipocyte Differentiation and Growth

et al. 2021

View full text Add to dashboard Cite

Barley sprouts are known to have several effective physiological activities. In this study, the anti-obesity effect of a barley sprout hot water extract (BSE) was confirmed. Saponarin was quantitatively analyzed in BSE using HPLC, and the inhibitory effect on 3T3-L1 pre-adipocyte differentiation into adipocytes was confirmed by Oil Red O staining, TG assay, and Western blotting. In addition, the inhibitory effect of BSE on adipocyte growth was confirmed through glucose uptake and lipolysis of adipocytes. C57/BL/6N mice were induced to obesity with a high-fat diet, and BSE was administered to confirm the effect on an animal model. Weight gain, morphological changes in adipose tissue, changes in the food efficiency ratio, and blood biochemical changes were observed, and an improvement effect on fatty liver was confirmed. As a result, the anti-obesity effect of BSE was confirmed in vitro, and it was confirmed that this effect was also effective in vivo and that it could be helpful in the treatment of obesity-related diseases.

show abstract

“…Anti-obesity drugs are important not only for the purpose of treatment for weight loss but also for the improvement of the aforementioned diseases. Several U.S. Food and Drug Administration (FDA)-approved synthetic drugs, as well as obesity therapy, have been reported to be helpful in weight loss and the management of metabolic diseases, but they have side effects when used for long periods [ 3 , 4 , 5 ]. Therefore, many researchers have studied the anti-obesity effects of natural products with superior safety [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes

Jee

Lee

et al. 2021

IJMS

View full text Add to dashboard Cite

Obesity is a risk factor for metabolic diseases including type 2 diabetes, nonalcoholic steatohepatitis (NASH), heart diseases, and cancer. This study aimed to investigate the anti-obesity effect of Polygalin C (PC) isolated from Polygala japonica Houtt. in 3T3-L1 adipocytes. Based on Oil Red O assay results, PC significantly decreased lipid accumulation compared to the control. We found that PC suppressed adipogenesis transcription factors including peroxisome proliferator-activated receptor γ (PPAR γ) and CCAAT/enhancer-binding protein (C/EBP) α, and lipogenic factors such as sterol regulatory element-binding protein 1c (SREBP 1c) and fatty acid synthase (FAS), in 3T3-L1 adipocytes using Western blotting and real-time polymerase chain reaction (PCR). Moreover, PC inhibited the differentiation of 3T3-L1 cells by regulating the AMP-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) and mitogen-activated protein kinase/protein kinase B (MAPK/Akt) signaling pathways. Additionally, we confirmed that PC inhibited early adipogenesis factors C/EBP β and C/EBP δ. Therefore, PC inhibited adipogenesis and lipogenesis in vitro. Thus, PC appears to exert potential therapeutic effects on obesity by suppressing lipid metabolism.

show abstract

Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

Cited by 88 publications

References 71 publications

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management

A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management

Anti-Obesity Effect of Hot Water Extract of Barley Sprout through the Inhibition of Adipocyte Differentiation and Growth

Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes

Contact Info

Product

Resources

About